 "Aurobindo Pharma posts net profit of Rs 92 cr in Q3")
The Hyderabad-based firm had posted a net loss of Rs 28.54 crore for the corresponding period of previous fiscal.
Consolidated net sales of the company rose to Rs 1,551.95 crore for the third quarter, as compared to Rs 1,263.73 crore for the same period of 2011-12 fiscal, Aurobindo Pharma Ltd said in a statement.
"We continue to see traction on our performance both in sales and earnings on year on year basis on account of improved business mix in formulations from new product approvals and launches in the US market," Aurobindo Pharma Ltd Managing Director N Govindarajan said.
He added that during the quarter, the US Food and Drug Administration (USFDA) cleared its two units and the health regulator has started approving products from these facilities.
"These will pave the way for consolidating injectable formulations business," Govindarajan added.
The company said its board also approved an interim dividend of 100%, Re 1 per equity share of Re 1 for the year 2012-13.
Shares of Aurobindo Pharma today ended at Rs 186.55 on the BSE, down 3.07% from their previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%